vs
Side-by-side financial comparison of HCW Biologics Inc. (HCWB) and Iterum Therapeutics plc (ITRM). Click either name above to swap in a different company.
HCW Biologics Inc. is the larger business by last-quarter revenue ($394.8K vs $390.0K, roughly 1.0× Iterum Therapeutics plc). HCW Biologics Inc. runs the higher net margin — -854.4% vs -2302.3%, a 1447.9% gap on every dollar of revenue. HCW Biologics Inc. produced more free cash flow last quarter ($-2.9M vs $-7.5M).
HCW Biologics Inc. is a clinical-stage biotechnology company focused on researching and developing novel immunotherapies and biological products targeting unmet medical needs in oncology, chronic inflammatory disorders, and autoimmune diseases. It primarily operates in the U.S., advancing multiple pipeline candidates through early to mid-stage clinical trials.
Iterum Therapeutics plc is a clinical-stage biopharmaceutical company specializing in developing innovative anti-infective therapies to treat infections caused by multi-drug resistant bacteria. Its lead product candidate targets indications including community-acquired bacterial pneumonia and complicated urinary tract infections, addressing unmet medical needs across global healthcare markets.
HCWB vs ITRM — Head-to-Head
Income Statement — Q4 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $394.8K | $390.0K |
| Net Profit | $-3.4M | $-9.0M |
| Gross Margin | 20.0% | — |
| Operating Margin | -795.9% | -1982.3% |
| Net Margin | -854.4% | -2302.3% |
| Revenue YoY | -70.2% | — |
| Net Profit YoY | 68.4% | -47.3% |
| EPS (diluted) | $-10.47 | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $390.0K | ||
| Q4 24 | $394.8K | — | ||
| Q3 24 | $426.4K | — | ||
| Q2 24 | $618.9K | — | ||
| Q1 24 | $1.1M | — | ||
| Q4 23 | $1.3M | — | ||
| Q3 23 | $853.1K | — | ||
| Q2 23 | $622.8K | — |
| Q3 25 | — | $-9.0M | ||
| Q4 24 | $-3.4M | — | ||
| Q3 24 | $-3.9M | — | ||
| Q2 24 | $-15.3M | — | ||
| Q1 24 | $-7.5M | — | ||
| Q4 23 | $-10.7M | — | ||
| Q3 23 | $-4.9M | — | ||
| Q2 23 | $-4.3M | — |
| Q3 25 | — | — | ||
| Q4 24 | 20.0% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 29.2% | — | ||
| Q1 24 | 54.6% | — | ||
| Q4 23 | 19.1% | — | ||
| Q3 23 | 20.5% | — | ||
| Q2 23 | 19.3% | — |
| Q3 25 | — | -1982.3% | ||
| Q4 24 | -795.9% | — | ||
| Q3 24 | -864.1% | — | ||
| Q2 24 | -2445.8% | — | ||
| Q1 24 | -665.1% | — | ||
| Q4 23 | -813.3% | — | ||
| Q3 23 | -595.2% | — | ||
| Q2 23 | -724.2% | — |
| Q3 25 | — | -2302.3% | ||
| Q4 24 | -854.4% | — | ||
| Q3 24 | -915.1% | — | ||
| Q2 24 | -2469.1% | — | ||
| Q1 24 | -662.8% | — | ||
| Q4 23 | -806.7% | — | ||
| Q3 23 | -578.9% | — | ||
| Q2 23 | -691.1% | — |
| Q3 25 | — | $-0.20 | ||
| Q4 24 | $-10.47 | — | ||
| Q3 24 | $-4.13 | — | ||
| Q2 24 | $-16.16 | — | ||
| Q1 24 | $-0.20 | — | ||
| Q4 23 | $-0.30 | — | ||
| Q3 23 | $-0.14 | — | ||
| Q2 23 | $-0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.7M | $11.0M |
| Total DebtLower is stronger | $7.4M | $20.0M |
| Stockholders' EquityBook value | $-6.8M | $-7.4M |
| Total Assets | $30.2M | $32.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $11.0M | ||
| Q4 24 | $4.7M | — | ||
| Q3 24 | $998.2K | — | ||
| Q2 24 | $1.2M | — | ||
| Q1 24 | $4.1M | — | ||
| Q4 23 | $3.6M | — | ||
| Q3 23 | $11.2M | — | ||
| Q2 23 | $17.4M | — |
| Q3 25 | — | $20.0M | ||
| Q4 24 | $7.4M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $8.3M | — | ||
| Q4 23 | $6.3M | — | ||
| Q3 23 | $6.3M | — | ||
| Q2 23 | $6.4M | — |
| Q3 25 | — | $-7.4M | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | $-10.0M | — | ||
| Q2 24 | $-6.3M | — | ||
| Q1 24 | $8.7M | — | ||
| Q4 23 | $13.5M | — | ||
| Q3 23 | $23.9M | — | ||
| Q2 23 | $28.6M | — |
| Q3 25 | — | $32.5M | ||
| Q4 24 | $30.2M | — | ||
| Q3 24 | $26.6M | — | ||
| Q2 24 | $26.8M | — | ||
| Q1 24 | $30.4M | — | ||
| Q4 23 | $28.5M | — | ||
| Q3 23 | $35.6M | — | ||
| Q2 23 | $39.5M | — |
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.95× | — | ||
| Q4 23 | 0.47× | — | ||
| Q3 23 | 0.27× | — | ||
| Q2 23 | 0.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.8M | $-7.4M |
| Free Cash FlowOCF − Capex | $-2.9M | $-7.5M |
| FCF MarginFCF / Revenue | -746.8% | -1912.6% |
| Capex IntensityCapex / Revenue | 28.7% | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-14.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-7.4M | ||
| Q4 24 | $-2.8M | — | ||
| Q3 24 | $-2.9M | — | ||
| Q2 24 | $-4.9M | — | ||
| Q1 24 | $-3.6M | — | ||
| Q4 23 | $-3.9M | — | ||
| Q3 23 | $-5.6M | — | ||
| Q2 23 | $-9.4M | — |
| Q3 25 | — | $-7.5M | ||
| Q4 24 | $-2.9M | — | ||
| Q3 24 | $-3.0M | — | ||
| Q2 24 | $-4.9M | — | ||
| Q1 24 | $-3.7M | — | ||
| Q4 23 | $-7.6M | — | ||
| Q3 23 | $-6.2M | — | ||
| Q2 23 | $-10.9M | — |
| Q3 25 | — | -1912.6% | ||
| Q4 24 | -746.8% | — | ||
| Q3 24 | -695.0% | — | ||
| Q2 24 | -788.7% | — | ||
| Q1 24 | -331.4% | — | ||
| Q4 23 | -574.8% | — | ||
| Q3 23 | -729.0% | — | ||
| Q2 23 | -1757.9% | — |
| Q3 25 | — | 3.1% | ||
| Q4 24 | 28.7% | — | ||
| Q3 24 | 8.7% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 11.5% | — | ||
| Q4 23 | 280.6% | — | ||
| Q3 23 | 73.9% | — | ||
| Q2 23 | 249.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
